1-萘乙胺盐酸盐 | 4735-50-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-萘乙胺盐酸盐
• 中文别名: 2-萘乙胺
• 英文名称: 2-naphthalen-1-yl-ethylamine
• 英文别名: 2-(1'-naphthyl)-ethyl-amine；2-(naphthalen-1-yl)ethanamine；2-(naphthalen-1-yl)ethan-1-amine；1-Naphthaleneethylamine；2-naphthalen-1-ylethanamine
• CAS: 4735-50-6
• 化学式: C₁₂H₁₃N
• mdl: MFCD01529866
• 分子量: 171.242
• InChiKey: RUJHATQMIMUYKD-UHFFFAOYSA-N

物化性质

• 熔点：
  212-213 °C (decomp)
• 沸点：
  170-173 °C(Press: 16 Torr)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存储于室温、避光且充满惰性气体的环境中。

反应信息

• 作为反应物：
  描述：

  1-萘乙胺盐酸盐 在 sodium tetrahydroborate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 72.33h， 生成 1-[5-methoxy-2-(2-phenylethynyl)phenyl]-N-methyl-N-(2-naphthalen-1-ylethyl)propan-2-amine
  参考文献：
  名称：

  2-Ethynylbenzenealkanamines. A new class of calcium entry blockers

  摘要：

  A series of 2-(aryl- or alkylethynyl)benzenealkanamines were synthesized. They exhibit antihypertensive activity in spontaneously hypertensive rats and coronary vasodilator activity with minimal negative inotropic activity in the "Langendorff" guinea pig heart in vitro. They have been shown to exert their activity by inhibition of Ca2+ influx across cell membranes. Optimal activity is found among the N-(arylethyl)-5-methoxy-alpha-methyl-2-(phenylethynyl)ben zeneethanamines and -propanamines.

  DOI：

  10.1021/jm00398a023
• 作为产物：
  描述：

  甲基萘 在 18-冠醚-6 N-溴代丁二酰亚胺(NBS) 、 lithium aluminium tetrahydride 作用下， 以 四氯化碳 、 二甲基亚砜 为溶剂， 反应 24.0h， 生成 1-萘乙胺盐酸盐
  参考文献：
  名称：

  荧光激发电荷转移复合物形成的构象效应

  摘要：

  通过研究某些ω-（1-萘基）-N-烷基吡咯的荧光量子产率和寿命随溶剂极性变化的变化，可以得出结论，受激配合物的构象对荧光的波长影响很小，但确实对辐射衰变过程和非辐射衰变过程的相对效率有影响。

  DOI：

  10.1039/f19827803467
• 作为试剂：
  描述：

  lead(II) bromide 、 1-乙基溴化吡啶 在 1-萘乙胺盐酸盐 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 以67.5 %的产率得到
  参考文献：
  名称：

  Boosted Second Harmonic Generation of a Chiral Hybrid Lead Halide Resonant to Charge Transfer Exciton from Metal Halide Octahedra to Ligand

  摘要：

  Chiral hybrid organic–inorganic metal halides (HOMHs) offer an ideal platform for the advancement of second‐order nonlinear optical (NLO) materials owing to their inherent noncentrosymmetric structures. The enhancement of optical nonlinearity of chiral HOMHs could be achieved by matching the free exciton and/or self‐trapped exciton energy levels with desired NLO frequencies. However, the current scarcity of resonance modes and low resonance ratio hamper the further improvements of NLO performance. Herein, we propose a new resonant channel of charge transfer (CT) excited states from metal halide polyhedra to organic ligand to boost the second‐order optical nonlinearity of chiral HOMHs. The model lead halide (C₇H₁₀N)PbBr₃ (C₇H₁₀N=1‐ethylpyridinium) exhibits a drastically enhanced second harmonic generation in resonance to the deep CT exciton energy, with intensity of up to 111.0 times that of KDP and 10.9 times that of urea. The effective NLO coefficient has been determined to be as high as ~40.2 pm V⁻¹, balanced with a large polarization ratio and high laser damage threshold. This work highlights the contribution of organic ligands in the construction of a resonant channel for enhancing second‐order NLO coefficients of metal halides, and thus provides guidelines for designing new chiral HOMHs materials for advanced nonlinear photonic applications.

  DOI：

  10.1002/anie.202400644

文献信息

• [EN] PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN ANTAGONISTE DU RÉCEPTEUR DE L'ENDOTHÉLINE
  申请人：CIPLA LTD

  公开号：WO2013057468A1

  公开（公告）日：2013-04-25

  The present invention relates to a novel process for the preparation of a compound of formula (I) wherein R is a methyl or methoxy group; to certain novel intermediates prepared in such a process and their use.

  本发明涉及一种新型制备式(I)化合物的方法，其中R为甲基或甲氧基；以及在这种方法中制备的某些新型中间体及其用途。
• [EN] SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS<br/>[FR] DERIVES DE 4-ALCOXYOXAZOLE SUBSTITUES EN TANT QU'AGONISTES DES RECEPTEURS PPAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004041275A1

  公开（公告）日：2004-05-21

  The present invention relates to compounds of formula (I) wherein R1 to R8 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

  本发明涉及式（I）的化合物，其中R1至R8和n如描述和权利要求中所定义，并且其药学上可接受的盐和酯。这些化合物可用于治疗疾病，如糖尿病。
• Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents
  作者：Bharat K. Trivedi、Ann Holmes、Terri L. Stoeber、C. John Blankley、W. Howard Roark、Joseph A. Picard、Mary K. Shaw、Arnold D. Essenburg、Richard L. Stanfield、Brian R. Krause

  DOI：10.1021/jm00074a011

  日期：1993.10

  We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia. For this series of compounds, the in vitro ACAT inhibitory activity

  我们合成了一系列的N-苯基-N'-芳烷基和N-苯基-N'-（1-苯基环烷基）脲作为酰基辅酶A：胆固醇酰基转移酶（ACAT）的抑制剂。人们认为这种细胞内酶负责饮食中胆固醇的酯化。因此抑制这种酶可以减少饮食引起的高胆固醇血症。对于这一系列化合物，通过增加苯环上2,6-取代基的体积来提高体外ACAT抑制活性。此外，我们发现芳环的间距对于ACAT抑制活性至关重要。离必需的2,6-二异丙基苯基部分5个原子的苯环对于体外活性而言是最佳的。N'-苯基部分被α取代增强了体外效能。就苯基环烷基脲而言，ACAT抑制活性与环烷基环的大小无关。从该系列类似物中，发现在高胆固醇血症动物模型中以50 mg / kg的饮食施用时，具有出色的体外抑制ACAT效力的化合物25在体内可使血浆胆固醇降低73％。在此模型中，化合物25依赖于降低血浆胆固醇剂量，并且与Lederle ACAT抑制剂CL 277082一样有效。
• Benzyloxy derivatives as MAOB inhibitors
  申请人：Jolidon Synese

  公开号：US20050288367A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.

  这项发明涉及以下公式的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、n、m和o如规范中所定义。这些化合物是选择性单胺氧化酶β抑制剂，对治疗和预防阿尔茨海默病和老年性痴呆症以及其他中枢神经系统疾病有用。该发明还涉及制备这类化合物的方法和含有它们的药物组合物。
• Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
  申请人：Hormann Eugene Robert

  公开号：US20050209283A1

  公开（公告）日：2005-09-22

  The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

  本发明涉及用于核受体基础诱导基因表达系统的非甾体配体，以及一种调节外源基因表达的方法，其中包括一个包含：DNA结合结构域；配体结合结构域；转活化结构域；和一个配体的ecdysone受体复合物与包含外源基因和响应元件的DNA构建物接触；其中外源基因受响应元件控制，并且在配体存在的情况下DNA结合结构域与响应元件结合导致基因的激活或抑制。